...
首页> 外文期刊>The Biochemical Journal >Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents
【24h】

Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents

机译:多药耐药转运蛋白P糖蛋白具有独特但相互作用的细胞毒性药物和逆转剂结合位点

获取原文
获取原文并翻译 | 示例

摘要

P-Glycoprotein, the plasma membrane protein responsible for the multidrug resistance of some tumour cells, is an active transporter of a number of structurally unrelated hydrophobic drugs. We have characterized the modulation of its ATPase activity by a multidrug-resistance-related cytotoxic drug, vinblastine, and different multidrug-resistance-reversing agents, verapamil and the dihydropyridines nicardipine, nimodipine, nitrendipine, nifedipine and azidopine. P-Glycoprotein ATPase activity was measured by using native membrane vesicles containing large amounts of P-glycoprotein, prepared from the highly multidrug-resistant lung fibroblasts DC-3F/ADX. P-Glycoprotein ATPase is activated by verapamil and by nicardipine but not by vinblastine. Among the five dihydropyridines tested, the higher the hydrophobicity, the higher was the activation factor with respect to the basal activity and the lower was the half-maximal activating concentration. The vinblastine-specific binding on P-glycoprotein is reported by the inhibitions of the verapamil- and the nicardipine-stimulated ATPase. These inhibitions are purely competitive, which means that the bindings of vinblastine and verapamil, or vinblastine and nicardipine, on P-glycoprotein are mutually exclusive. In contrast, verapamil and nicardipine display mutually non-competitive interactions. This demonstrates the existence of two distinct specific sites for these two P-glycoprotein modulators on which they can bind simultaneously and separately to the vinblastine site. The nicardipine-stimulated ATPase activity in the presence of the other dihydropyridines shows mixed-type inhibitions. These dihydropyridines have thus different binding sites that interact mutually to decrease their respective, separately determined affinities. This could be due to steric constraints between sites close to each other. This is supported by the observation that vinblastine binding is not mutually exclusive with nifedipine or nitrendipine binding, whereas it is mutually exclusive with nicardipine. Moreover, verapamil binding also interacts with the Eve dihydropyridines by mixed inhibitions, with different destabilization factors. On the whole our enzymic data show that P-glycoprotein has distinct but interacting binding sites for various modulators of its ATPase function. [References: 42]
机译:P-糖蛋白是负责某些肿瘤细胞多药耐药性的质膜蛋白,是许多与结构无关的疏水性药物的活性转运蛋白。我们已经通过多药耐药相关的细胞毒性药物长春碱和不同的多药耐药逆转剂维拉帕米和二氢吡啶类尼卡地平,尼莫地平,尼群地平,硝苯地平和阿齐多平来调节其ATPase活性。通过使用含有大量P-糖蛋白的天然膜囊泡来测量P-糖蛋白ATPase活性,该膜囊泡是由高度耐多药性肺成纤维细胞DC-3F / ADX制备的。 P-糖蛋白ATP酶被维拉帕米和尼卡地平激活,但未被长春碱激活。在所测试的五种二氢吡啶中,疏水性越高,相对于基础活性而言,活化因子越高,而半数最大活化浓度越低。据报道,维拉帕米和尼卡地平刺激的ATPase抑制了长春碱对P-糖蛋白的特异性结合。这些抑制作用纯粹是竞争性的,这意味着长春碱和维拉帕米或长春碱和尼卡地平在P-糖蛋白上的结合是互斥的。相反,维拉帕米和尼卡地平表现出相互不竞争的相互作用。这证明了这两个P-糖蛋白调节剂存在两个不同的特异性位点,它们可以同时和分别结合到长春碱位点上。在其他二氢吡啶存在下,尼卡地平刺激的ATPase活性表现出混合型抑制作用。这些二氢吡啶因此具有不同的结合位点,所述结合位点相互相互作用以降低其各自的,分别确定的亲和力。这可能是由于彼此靠近的站点之间存在空间限制。长春碱的结合与硝苯地平或硝苯地平的结合并不互斥,而尼卡地平的结合并不互斥。此外,维拉帕米结合还通过具有不同去稳定因子的混合抑制作用与夏娃二氢吡啶相互作用。总体而言,我们的酶学数据表明,P-糖蛋白具有不同但相互作用的ATPase功能调节剂结合位点。 [参考:42]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号